Increased plasma asymmetric dimethylarginine is associated with cognitive deficits in patients with schizophrenia

Yang, Yuan-Jian; Xiong, Jian; Zhao, Ying; Zhan, Jin-Qiong; Chen, Haibo; Yan, Kun; Hu, Maorong; Yu, Bin; Wei, Bo

doi:10.1016/j.psychres.2016.10.015

Cited by 13 publications

(12 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of cognitive domains, such as processing speed, attention, working memory, visual memory, verbal learning, and executive function, have been reported to be impaired in schizophrenia. Our present study shows that schizophrenia patients displayed poorer performance in processing speed, working memory, attention, visual memory, and executive function than the normal controls, identical to previous studies [30,36]. IGF-2 has been strongly linked to cognition in the last decades [37].…”

Section: Plos Onesupporting

confidence: 89%

See 1 more Smart Citation

Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia

et al. 2020

Self Cite

View full text Add to dashboard Cite

BackgroundSchizophrenia is linked with abnormal brain neurodevelopment, on which IGF-2 (insulin-like growth factor-2) has a great impact. The purpose of this study was to assess the levels of serum IGF-2 and its binding proteins IGFBP-3 and IGFBP-7 in schizophrenia patients and the associations of these proteins with schizophrenia psychopathology and cognitive deficits. -Q, et al. (2020) Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia. PLoS ONE 15(3): e0226688. ConclusionsOur study demonstrates that serum IGF-2 was significantly correlated with negative and cognitive symptoms in patients with schizophrenia, suggesting that altered IGF-2 signaling may be implicated in the psychopathology and cognitive deficits in schizophrenia. BackgroundAccording to a hypothesis about schizophrenia, if an adult suffers from severe mental illness, the central nervous system must have developed in a disrupted manner [1,2]. This has been widely indicated by studies in areas of epidemiology, genetics and neuroimaging [3]. For example, structural brain abnormalities are apparent in the beginning stages of schizophrenia [4,5]; there were cases in which young people frequently suffered abnormal cognition and emotion abilities just before the appearance of the mental illness [6]; and primates suffering neonatal lesions had a disabled motion capability [7].As a type of insulin-like protein, insulin-like growth factor (IGF) is an integral component of the cell system in human bodies that serves as a communication channel regarding the physiological circumstances [8]. Accumulated evidence has convincingly demonstrated that IGF has an indispensable and crucial role to play in nerve growth [9]. During the development of brains, IGF signaling regulates the growth survival, maturations, and proliferation of many types of nerve cells, such as astrocytes, oligodendrocytes, NPC (nerve precursor cell) and NSC (nerve stem cell) [9]. In addition, IGF sends basic signals to NSC cells directing them to grow into particular lineages in early development and influences their specific biological roles in late development, with the help of other nerve signals [9]. Individuals suffering from IGF gene mutations are vulnerable to physically disabled growth, nanocephaly or intellectual disability [10,11,12].Two different IGF ligands, insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2), have drawn much attention in recent studies. Researchers have shown that IGF-1 signaling plays a role in schizophrenia pathogenesis [13,14,15]. Specifically, plasma IGF-1 levels were decreased in antipsychotic-naive schizophrenia patients and were inversely correlated with positive symptom scores and hallucination subscores [13]. Antipsychotic treatment can increase serum IGF-1 levels in schizophrenia patients, and those patients with a greater increase showed a reduction in positive symptom scores to a higher extent [14]. Palomino et al. studied and showed that the...

show abstract

Section: Plos Onesupporting

confidence: 89%

“…For the measurement of cognition, we used a set of neurocognition tests, the clinical dependability of which had already been verified and confirmed in population groups of Chinese people [29,30]. These tests consist of the following seven tasks:…”

Section: Measurement Of Psychopathological Symptoms and Cognitionmentioning

confidence: 99%

Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Deﬁcits of NO signaling is known to be linked with the pathogenesis of schizophrenia (Yanik et al, 2003). Yang et al found that increased plasma ADMA was associated with cognitive deﬁcits in patients with schizophrenia (Yang et al, 2016). Furthermore, Yu et al showed that atypical antipsychotic treatment could signiﬁcantly decrease plasma ADMA concentration and parallelly improve cognitive function in schizophrenia patients with acute exacerbation Yu et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Young rats with increased circulatory asymmetric dimethylarginine exhibited spatial deficit and alterations in dorsal hippocampus brain‐derived neurotrophic factor and asymmetric dimethylarginine: Effects of melatonin

Sheen

Tain

et al. 2019

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

Increased plasma concentration of asymmetric dimethylarginine (ADMA) can be encountered in chronic inﬂammatory disease, liver damage, renal failure, and multiple organ failure. In addition, an association between circulating ADMA and all‐cause mortality has been reported. Male Sprague‐Dawley rats, postnatal day (PND) 17 ± 1, received continuous ADMA infusion via an intraperitoneal pump. Spatial performance, as well as plasma and dorsal hippocampus ADMA and brain‐derived neurotrophic factor (BDNF) concentration, were examined and the effect of melatonin was tested. We found that a 4‐week continuous ADMA infusion in young rats caused spatial deficit. Furthermore, increased ADMA concentration and decreased BDNF expression were found in the plasma and dorsal hippocampus. Melatonin protected against these effects, alleviating spatial deficit and reducing the changes in plasma and dorsal hippocampus ADMA and BDNF concentration.

show abstract

“…Previous studies have demonstrated that plasma ADMA concentrations were increased in patients with schizophrenia relative to healthy individuals, but no association was found between plasma ADMA and the scores of psychiatric rating scales (14–16). We also found that plasma ADMA levels were elevated in schizophrenia patients and increased ADMA correlated with cognitive impairment (17). Zincir et al reported that treatment with antipsychotics in patients for 2 months could reduce plasma ADMA levels, while no correlation was observed between the improvement of psychiatric symptoms and the change of plasma ADMA (16).…”

Section: Introductionmentioning

confidence: 85%

“…The cognitive function of subjects was measured by a comprehensive battery of neurocognitive tests (17, 24, 25). These tests are commonly used in China, and their clinical reliability and validity have been evaluated in Chinese populations.…”

Section: Methodsmentioning

confidence: 99%

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia

Zhao

Zhan

et al. 2019

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

Cognitive deficits represent a core feature of schizophrenia. Previous studies have demonstrated that plasma asymmetric dimethylarginine (ADMA) was increased in patients with schizophrenia and correlated with cognitive impairments. Atypical antipsychotics can produce cognitive benefits in schizophrenia patients. In this study, we conducted a prospective observation trial to explore whether plasma ADMA may serve as an indicator for evaluating cognitive improvements induced by atypical antipsychotics in patients with schizophrenia. A total of 41 schizophrenia patients with acute exacerbation were enrolled and 29 patients completed this study. These recruited patients were drug-naive or had no exposure to antipsychotics for at least 3 months. Thirty healthy individuals were recruited as a control group. Positive and Negative Syndrome Scale (PANSS) and a neuropsychological battery were used to evaluate schizophrenic symptoms and cognitive function, respectively. Plasma ADMA was measured by high-performance liquid chromatography (HPLC). We found that schizophrenia patients with acute exacerbation had significantly poorer cognitive performances and higher plasma ADMA levels than control individuals (p < 0.05). After 2 months of atypical antipsychotic treatment, patients showed significant improvements in processing speed, working memory, attention, and executive function (all p < 0.01). Plasma ADMA levels in patients after treatment were significantly decreased compared to baseline (2.42 ± 0.84 vs. 1.55 ± 0.34 μmol/L; t = 6.491, p < 0.001). Correlation analysis reveals that there is a significant correlation of the decrease in ADMA with improvements in working memory (r = −0.413, p = 0.026) and attention (r = −0.417, p = 0.025). Collectively, our results suggest that atypical antipsychotics improve cognitive function in schizophrenia patients with acute exacerbation, in parallel with decreased plasma ADMA levels. Plasma ADMA levels may be an indicator of cognitive recovery in schizophrenia.

show abstract

Increased plasma asymmetric dimethylarginine is associated with cognitive deficits in patients with schizophrenia

Cited by 13 publications

References 34 publications

Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia

Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia

Young rats with increased circulatory asymmetric dimethylarginine exhibited spatial deficit and alterations in dorsal hippocampus brain‐derived neurotrophic factor and asymmetric dimethylarginine: Effects of melatonin

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia

Contact Info

Product

Resources

About